ЗА ТОЗИ ПОДКАСТ 🔗

Водещи:
Честота на актуализиране:
weekly
Средна дължина на звука:
29 minutes
Интервюта с гости
Има спонсори
Френски
Франция
147 епизода
от 15 Май 2023
episodic

ПОСЛЕДЕН ЕПИЗОД 🔗

Comment l’industrie pharmaceutique peut-elle contribuer à transformer l’accès aux soins, au-delà du développement des médicaments ? Dans cet épisode de Pharma Minds, je reçois Émilie Mercadal, cofondatrice de Rofim, une plateforme de télémédecine conçue pour faciliter l’accès à l’expertise médical…

ТЪРСЕНЕ на МИНАЛИ ЕПИЗОДИ

Търсене в минали епизоди на Pharma Minds.

ПРЕДИШНИ ЕПИЗОДИ

Fixer le prix d'une innovation, c'est déjà compliqué. Mais comment faire quand personne ne l'a encore utilisée ? Trop cher, le prix devient un frein à l'adoption. Trop bas, et le succès commercial peut paradoxalement faire perdre de l'argent à l'entreprise. Pour Émilie Mercadal, cofondatrice de R…
Et si standardiser les flux de patients permettait de mieux les soigner ? Dans cet épisode de Pharma minds, je reçois Loïc Lagarde, directeur général de la Clinique Pasteur à Toulouse. Ingénieur de formation, passé par Google, YouTube et l’entrepreneuriat avec Santé Discount, il apporte un regard …
Comment faire accepter le changement sans que les équipes aient le sentiment que leur travail passé est remis en question ? Pour Loïc Lagarde, dirigeant de la Clinique Pasteur à Toulouse, changer ne signifie pas que ce qu’on faisait avant était mauvais. Cela signifie que nos pratiques doivent évol…
What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG) and of the WHO Colla…
"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait …
What happens to pharmaceutical innovation when your competitive window shrinks from eight years to just three? In this episode of Pharma minds, I speak with Marine Baxendell, CFO and co-fonder at xcube.bio, about a fundamental shift in the economics of pharma innovation. Science is moving faster.…
MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders sta…
What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma …
What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most conseque…
Опровержение: Подкастът и произведенията на изкуството, вградени на тази страница, са от Nathalie Lahitte, което е собственост на неговия собственик и не е свързано с или одобрено от Listen Notes, Inc.